These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 14709941)

  • 1. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment.
    Shinkai K; Yoshimura R; Ueda N; Okamoto K; Nakamura J
    J Clin Psychopharmacol; 2004 Feb; 24(1):11-7. PubMed ID: 14709941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression.
    Ueda N; Yoshimura R; Shinkai K; Nakamura J
    Pharmacopsychiatry; 2002 Sep; 35(5):175-81. PubMed ID: 12237788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
    Yoshimura R; Mitoma M; Sugita A; Hori H; Okamoto T; Umene W; Ueda N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1034-7. PubMed ID: 17459550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of paroxetine on cerebrospinal fluid concentrations of neurotransmitter metabolites in depressed patients.
    Lundmark J; Wålinder J; Alling C; Manniche PM; Dalgaard L
    Eur Neuropsychopharmacol; 1994 Mar; 4(1):1-6. PubMed ID: 7515737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of milnacipran and paroxetine in outpatients with major depression.
    Sechter D; Vandel P; Weiller E; Pezous N; Cabanac F; Tournoux A;
    J Affect Disord; 2004 Dec; 83(2-3):233-6. PubMed ID: 15555719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of acute paroxetine treatment on the consumption of cigarette smoking and caffeine in depressed patients.
    Miyamoto K; Yoshimura R; Ueda N; Sugita A; Umene W; Hori H; Mitoma M; Nakamura J
    Hum Psychopharmacol; 2007 Oct; 22(7):483-90. PubMed ID: 17726723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.
    Morishita S; Arita S
    Hum Psychopharmacol; 2004 Aug; 19(6):405-8. PubMed ID: 15303244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran.
    Wakeno M; Kato M; Okugawa G; Fukuda T; Hosoi Y; Takekita Y; Yamashita M; Nonen S; Azuma J; Kinoshita T
    J Clin Psychopharmacol; 2008 Oct; 28(5):518-24. PubMed ID: 18794646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients.
    Higuchi H; Yoshida K; Takahashi H; Naito S; Kamata M; Ito K; Sato K; Tsukamoto K; Shimizu T; Nakanishi M; Hishikawa Y
    Hum Psychopharmacol; 2003 Jun; 18(4):255-9. PubMed ID: 12766929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan.
    Chang TT; Lêng CH; Wu JY; Lee SY; Wang YS; Chen YC; Lu RB
    Chin J Physiol; 2008 Dec; 51(6):387-93. PubMed ID: 19280883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism.
    Umene-Nakano W; Yoshimura R; Ueda N; Suzuki A; Ikenouchi-Sugita A; Hori H; Otani K; Nakamura J
    J Psychopharmacol; 2010 Dec; 24(12):1764-71. PubMed ID: 19825907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
    Vandel P; Sechter D; Weiller E; Pezous N; Cabanac F; Tournoux A; Panconi E
    Hum Psychopharmacol; 2004 Dec; 19(8):585-6. PubMed ID: 15570574
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential effects of milnacipran, fluvoxamine and paroxetine for inhibited and agitated depression.
    Morishita S; Arita S
    Eur Psychiatry; 2004 Nov; 19(7):450-1. PubMed ID: 15504656
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment.
    Sakakibara R; Ito T; Uchiyama T; Awa Y; Yamaguchi C; Hattori T
    Urol Int; 2008; 81(3):335-9. PubMed ID: 18931554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Morishita S; Arita S
    Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine.
    Ko HC; Lu RB; Shiah IS; Hwang CC
    Biol Psychiatry; 1997 Apr; 41(7):774-81. PubMed ID: 9084896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating depression with SNRIs: who will benefit most?
    Isaac MT
    CNS Spectr; 2008 Jul; 13(7 Suppl 11):15-21. PubMed ID: 18622370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients.
    Yoshimura R; Umene-Nakano W; Suzuki A; Ueda N; Miyamoto K; Ikenouchi-Sugita A; Hori H; Otani K; Nakamura J
    Hum Psychopharmacol; 2009 Aug; 24(6):489-94. PubMed ID: 19606452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venlafaxine, paroxetine and milnacipran for major depressive disorder: a pragmatic 24-week study.
    Chuang HY; Chang YH; Cheng LY; Wang YS; Chen SL; Chen SH; Chu CH; Lee IH; Chen PS; Yeh TL; Yang YK; Lu RB
    Chin J Physiol; 2014 Oct; 57(5):265-70. PubMed ID: 25241986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine.
    Ikenouchi-Sugita A; Yoshimura R; Hori H; Umene-Nakano W; Ueda N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1451-3. PubMed ID: 19664676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.